Skip to main content
Top
Published in: Endocrine 2/2012

01-10-2012 | Review

Testosterone and heart failure

Authors: Maurizio Volterrani, Giuseppe Rosano, Ferdinando Iellamo

Published in: Endocrine | Issue 2/2012

Login to get access

Abstract

Testosterone deficiency is a generalized phenomenon seen in the course of chronic heart failure (CHF). Reduction in circulating testosterone level is a predictor of deterioration of functional capacity over time, underscoring the role of testosterone deficiency in CHF. Anabolic hormones are determinants of exercise capacity and circulating levels of anabolic hormones strongly determine muscle mass and strength. Testosterone deficiency is involved in the pathophysiology of CHF, contributing to some features of this syndrome, such as the reduced muscle mass, abnormal energy handling, fatigue, dyspnea and, finally, cachexia. This review summarizes current knowledge on the role of testosterone deficiency in the pathophysiology of CHF, gaining insights from the potential implications of testosterone as supplementation therapy.
Literature
1.
go back to reference S.D. Anker, T.P. Chua, P. Ponikowski et al., Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef S.D. Anker, T.P. Chua, P. Ponikowski et al., Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef
2.
go back to reference Y. Moriyama, H. Yasue, M. Yoshimura et al., The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J. Clin. Endocrinol. Metab. 85, 1834–1840 (2000)PubMedCrossRef Y. Moriyama, H. Yasue, M. Yoshimura et al., The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J. Clin. Endocrinol. Metab. 85, 1834–1840 (2000)PubMedCrossRef
3.
go back to reference P.E. Kontoleon, M.I. Anastasiou-Nana, P.D. Papapetrou et al., Hormonal profile in patients with congestive heart failure. Int. J. Cardiol. 87, 179–183 (2003)PubMedCrossRef P.E. Kontoleon, M.I. Anastasiou-Nana, P.D. Papapetrou et al., Hormonal profile in patients with congestive heart failure. Int. J. Cardiol. 87, 179–183 (2003)PubMedCrossRef
4.
go back to reference P.J. Pugh, R.D. Jones, J.N. West, T.H. Jones, K.S. Channer, Testosterone treatment for men with chronic heart failure. Heart 90, 446–447 (2004)PubMedCrossRef P.J. Pugh, R.D. Jones, J.N. West, T.H. Jones, K.S. Channer, Testosterone treatment for men with chronic heart failure. Heart 90, 446–447 (2004)PubMedCrossRef
5.
go back to reference C.J. Malkin, T.H. Jones, K.S. Channer, Testosterone in chronic heart failure. Front. Horm. Res. 37, 183–196 (2009)PubMedCrossRef C.J. Malkin, T.H. Jones, K.S. Channer, Testosterone in chronic heart failure. Front. Horm. Res. 37, 183–196 (2009)PubMedCrossRef
6.
go back to reference S.D. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef S.D. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef
7.
go back to reference E.A. Jankowska, B. Biel, J. Majda et al., Anabolic deficiency in men with chronic heart failure prevalence and detrimental impact on survival. Circulation 114, 1829–1837 (2006)PubMedCrossRef E.A. Jankowska, B. Biel, J. Majda et al., Anabolic deficiency in men with chronic heart failure prevalence and detrimental impact on survival. Circulation 114, 1829–1837 (2006)PubMedCrossRef
8.
go back to reference E.A. Jankowska, G. Gerasimos Filippatos, B. Ponikowska et al., Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Cardiac Fail. 15, 442–450 (2009)CrossRef E.A. Jankowska, G. Gerasimos Filippatos, B. Ponikowska et al., Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Cardiac Fail. 15, 442–450 (2009)CrossRef
9.
go back to reference N. Pitteloud, V.K. Mootha, A.A. Dwyer et al., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28, 1636–1642 (2005)PubMedCrossRef N. Pitteloud, V.K. Mootha, A.A. Dwyer et al., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28, 1636–1642 (2005)PubMedCrossRef
10.
go back to reference M. Izquierdo, K. Hakkinen, A. Anton et al., Maximal strength and power, endurance performance, and serum hormones in middle-aged and elderly men. Med. Sci. Sports Exerc. 33, 1577–1587 (2001)PubMedCrossRef M. Izquierdo, K. Hakkinen, A. Anton et al., Maximal strength and power, endurance performance, and serum hormones in middle-aged and elderly men. Med. Sci. Sports Exerc. 33, 1577–1587 (2001)PubMedCrossRef
11.
go back to reference Z.R. Haydar, M.R. Blackman, J.D. Tobin, J.G. Wright, J.L. Fleg, The relationship between aerobic exercise capacity and circulating IGF1 levels in healthy men and women. J. Am. Geriatr. Soc. 48, 139–145 (2000)PubMed Z.R. Haydar, M.R. Blackman, J.D. Tobin, J.G. Wright, J.L. Fleg, The relationship between aerobic exercise capacity and circulating IGF1 levels in healthy men and women. J. Am. Geriatr. Soc. 48, 139–145 (2000)PubMed
12.
go back to reference F. Hartgens, H. Kuipers, J.A. Wijnen, H.A. Keizer, Body composition, cardiovascular risk factors and liver function in long-term androgenic–anabolic steroids using body builders three months after drug withdrawal. Int. J. Sports Med. 17, 429–433 (1996)PubMedCrossRef F. Hartgens, H. Kuipers, J.A. Wijnen, H.A. Keizer, Body composition, cardiovascular risk factors and liver function in long-term androgenic–anabolic steroids using body builders three months after drug withdrawal. Int. J. Sports Med. 17, 429–433 (1996)PubMedCrossRef
13.
go back to reference I. Sinha-Hikim, J. Artaza, L. Woodhouse et al., Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. 283, 154–164 (2002) I. Sinha-Hikim, J. Artaza, L. Woodhouse et al., Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. 283, 154–164 (2002)
14.
go back to reference T.W. Storer, L. Magliano, L. Woodhouse et al., Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J. Clin. Endocrinol. Metab. 88, 1478–1485 (2003)PubMedCrossRef T.W. Storer, L. Magliano, L. Woodhouse et al., Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J. Clin. Endocrinol. Metab. 88, 1478–1485 (2003)PubMedCrossRef
15.
go back to reference R. Wolfe, A. Ferrando, M. Sheffield-Moore, R. Urban, Testosterone and muscle protein metabolism. Mayo Clin. Proc. 75(Suppl), S55–S60 (2000)PubMed R. Wolfe, A. Ferrando, M. Sheffield-Moore, R. Urban, Testosterone and muscle protein metabolism. Mayo Clin. Proc. 75(Suppl), S55–S60 (2000)PubMed
16.
go back to reference A.A. Ferrando, M. Sheffield-Moore, C.W. Yeckel et al., Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 282, E601–E607 (2002)PubMed A.A. Ferrando, M. Sheffield-Moore, C.W. Yeckel et al., Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 282, E601–E607 (2002)PubMed
17.
go back to reference F. Kadi, Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br. J. Pharmacol. 154, 522–528 (2008)PubMedCrossRef F. Kadi, Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br. J. Pharmacol. 154, 522–528 (2008)PubMedCrossRef
18.
go back to reference R. Hambrecht, E. Fiehn, J. Yu et al., Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J. Am. Coll. Cardiol. 29, 1067–1073 (1997)PubMedCrossRef R. Hambrecht, E. Fiehn, J. Yu et al., Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J. Am. Coll. Cardiol. 29, 1067–1073 (1997)PubMedCrossRef
19.
go back to reference A.J. Coats, A.L. Clark, M. Piepoli, M. Volterrani, P.A. Poole-Wilson, Symptoms and quality of life in heart failure: the muscle hypothesis. Br. Heart J. 72, S36–S39 (1994)PubMedCrossRef A.J. Coats, A.L. Clark, M. Piepoli, M. Volterrani, P.A. Poole-Wilson, Symptoms and quality of life in heart failure: the muscle hypothesis. Br. Heart J. 72, S36–S39 (1994)PubMedCrossRef
20.
go back to reference M.F. Piepoli, A. Kaczmarek, D.P. Francis et al., Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 114, 126–134 (2006)PubMedCrossRef M.F. Piepoli, A. Kaczmarek, D.P. Francis et al., Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 114, 126–134 (2006)PubMedCrossRef
21.
go back to reference M. Piepoli, A.L. Clark, M. Volterrani, S. Adamopoulos, P. Sleight, A.J. Coats, Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 93, 940–952 (1996)PubMedCrossRef M. Piepoli, A.L. Clark, M. Volterrani, S. Adamopoulos, P. Sleight, A.J. Coats, Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 93, 940–952 (1996)PubMedCrossRef
22.
go back to reference F. Iellamo, J.A. Sala-Mercado, M. Ichinose et al., Spontaneous baroreflex control of heart rate during exercise and muscle metaboreflex activation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 293, H1929–H1936 (2007)PubMedCrossRef F. Iellamo, J.A. Sala-Mercado, M. Ichinose et al., Spontaneous baroreflex control of heart rate during exercise and muscle metaboreflex activation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 293, H1929–H1936 (2007)PubMedCrossRef
23.
go back to reference S.D. Anker, P. Ponikowski, S. Varney et al., Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef S.D. Anker, P. Ponikowski, S. Varney et al., Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef
24.
go back to reference P.P. Ponikowski, T.P. Chua, D.P. Francis et al., Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 104, 2324–2330 (2001)PubMedCrossRef P.P. Ponikowski, T.P. Chua, D.P. Francis et al., Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 104, 2324–2330 (2001)PubMedCrossRef
25.
go back to reference M.F. Piepoli, A.C. Scott, A. Capucci, A.J. Coats, Skeletal muscle training in chronic heart failure. Acta Physiol. Scand. 171, 295–303 (2001)PubMedCrossRef M.F. Piepoli, A.C. Scott, A. Capucci, A.J. Coats, Skeletal muscle training in chronic heart failure. Acta Physiol. Scand. 171, 295–303 (2001)PubMedCrossRef
26.
go back to reference G. Caminiti, M. Volterrani, F. Iellamo et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef G. Caminiti, M. Volterrani, F. Iellamo et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef
27.
go back to reference M. Czesla, G. Mehlhorn, D. Fritzsche, G. Asmussen, Cardiomyoplasty-improvement of muscle fibre type transformation by anabolic steroid. J. Mol. Cell Cardiol. 29, 2989–2996 (1997)PubMedCrossRef M. Czesla, G. Mehlhorn, D. Fritzsche, G. Asmussen, Cardiomyoplasty-improvement of muscle fibre type transformation by anabolic steroid. J. Mol. Cell Cardiol. 29, 2989–2996 (1997)PubMedCrossRef
28.
go back to reference I. Ustünel, G. Akkoyunlu, R. Demir, The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: a histochemical, morphometric and ultrastructural study. Anat. Histol. Embryol. 32, 70–79 (2003)PubMedCrossRef I. Ustünel, G. Akkoyunlu, R. Demir, The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: a histochemical, morphometric and ultrastructural study. Anat. Histol. Embryol. 32, 70–79 (2003)PubMedCrossRef
29.
go back to reference C.J. Malkin, P.J. Pugh, J.N. West, E.J.R. Van Beek, T.H. Jones, K.S. Channer, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57–64 (2006)PubMedCrossRef C.J. Malkin, P.J. Pugh, J.N. West, E.J.R. Van Beek, T.H. Jones, K.S. Channer, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57–64 (2006)PubMedCrossRef
30.
go back to reference A.M. Traish, F. Saad, R.J. Feeley, A. Guay, The dark side of testosterone review deficiency: III: cardiovascular disease. J. Androl. 30, 477–494 (2009)PubMedCrossRef A.M. Traish, F. Saad, R.J. Feeley, A. Guay, The dark side of testosterone review deficiency: III: cardiovascular disease. J. Androl. 30, 477–494 (2009)PubMedCrossRef
31.
go back to reference T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 18, 9–13 (2007)PubMedCrossRef T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 18, 9–13 (2007)PubMedCrossRef
32.
go back to reference K. Saltiki, G. Papageorgiou, P. Voidonikola et al., Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels. Endocrine 37, 329–335 (2010)PubMedCrossRef K. Saltiki, G. Papageorgiou, P. Voidonikola et al., Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels. Endocrine 37, 329–335 (2010)PubMedCrossRef
33.
go back to reference P.J. Pugh, T.H. Jones, K.S. Channer, Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur. Heart J. 24, 909–915 (2003)PubMedCrossRef P.J. Pugh, T.H. Jones, K.S. Channer, Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur. Heart J. 24, 909–915 (2003)PubMedCrossRef
34.
go back to reference K. Swedberg, J. Cleland, H. Dargie et al., Guidelines on the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Heart J. 26, 1115–1140 (2005)PubMedCrossRef K. Swedberg, J. Cleland, H. Dargie et al., Guidelines on the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Heart J. 26, 1115–1140 (2005)PubMedCrossRef
35.
go back to reference J.L. Fleg, I.L. Pina, G.J. Balady et al., Assessment of functional capacity in clinical and research applications. An advisory from the Committee on Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 102, 1591–1597 (2000)PubMedCrossRef J.L. Fleg, I.L. Pina, G.J. Balady et al., Assessment of functional capacity in clinical and research applications. An advisory from the Committee on Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 102, 1591–1597 (2000)PubMedCrossRef
36.
go back to reference D. Francis, W. Shamin, L.C. Davies et al., Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2 slope and peak VO2. Eur. Heart J. 21, 154–161 (2000)PubMedCrossRef D. Francis, W. Shamin, L.C. Davies et al., Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2 slope and peak VO2. Eur. Heart J. 21, 154–161 (2000)PubMedCrossRef
37.
go back to reference R. Arena, J. Myers, J. Abella, Development of a ventilatory classification system in patients with heart failure. Circulation 115, 2410–2417 (2007)PubMedCrossRef R. Arena, J. Myers, J. Abella, Development of a ventilatory classification system in patients with heart failure. Circulation 115, 2410–2417 (2007)PubMedCrossRef
38.
go back to reference R. Martin-Du Pan, Androgen deficiency in women: indications and risks of treatment with testosterone or DHEA. Rev. Med. Suisse 3, 792–796 (2007)PubMed R. Martin-Du Pan, Androgen deficiency in women: indications and risks of treatment with testosterone or DHEA. Rev. Med. Suisse 3, 792–796 (2007)PubMed
40.
go back to reference K. Miller, B. Biller, C. Beauregard et al., Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683–1690 (2006)PubMedCrossRef K. Miller, B. Biller, C. Beauregard et al., Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683–1690 (2006)PubMedCrossRef
41.
go back to reference K.K. Miller, B.M.K. Biller, A. Schaub et al., Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J. Clin. Endocrinol. Metab. 92, 2474–2479 (2007)PubMedCrossRef K.K. Miller, B.M.K. Biller, A. Schaub et al., Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J. Clin. Endocrinol. Metab. 92, 2474–2479 (2007)PubMedCrossRef
42.
go back to reference F. Iellamo, M. Volterrani, G. Caminiti et al., Testosterone therapy in women with chronic heart failure: a pilot double-blind randomized placebo controlled study. J. Am. Coll. Cardiol. 56, 1310–1316 (2010)PubMedCrossRef F. Iellamo, M. Volterrani, G. Caminiti et al., Testosterone therapy in women with chronic heart failure: a pilot double-blind randomized placebo controlled study. J. Am. Coll. Cardiol. 56, 1310–1316 (2010)PubMedCrossRef
43.
go back to reference J. Shifren, G. Braunstein, J. Simon et al., Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682–688 (2000)PubMedCrossRef J. Shifren, G. Braunstein, J. Simon et al., Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682–688 (2000)PubMedCrossRef
44.
go back to reference G. Wittert, I. Chapman, M. Haren, S. Mackintosh, P. Coates, J. Morley, Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Biol Sci Med Sci 58, 618–625 (2003)CrossRef G. Wittert, I. Chapman, M. Haren, S. Mackintosh, P. Coates, J. Morley, Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Biol Sci Med Sci 58, 618–625 (2003)CrossRef
45.
go back to reference C.J. Malkin, T.H. Jones, K.S. Channer, The effect of testosterone on insulin sensitivity in men with heart failure. Eur. J. Heart Fail. 9, 44–50 (2007)PubMedCrossRef C.J. Malkin, T.H. Jones, K.S. Channer, The effect of testosterone on insulin sensitivity in men with heart failure. Eur. J. Heart Fail. 9, 44–50 (2007)PubMedCrossRef
46.
go back to reference S. von Haehling, W. Doehner, S.D. Anker, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73, 298–309 (2007)CrossRef S. von Haehling, W. Doehner, S.D. Anker, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73, 298–309 (2007)CrossRef
47.
go back to reference J.W. Swan, S.D. Anker, C. Walton et al., Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 30, 527–532 (1997)PubMedCrossRef J.W. Swan, S.D. Anker, C. Walton et al., Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 30, 527–532 (1997)PubMedCrossRef
48.
go back to reference E. Ingelsson, J. Sundstrom, J. Amlov, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef E. Ingelsson, J. Sundstrom, J. Amlov, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef
49.
go back to reference N. Suskin, R.S. McKelvie, R.J. Burns et al., Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 21, 1368–1375 (2000)PubMedCrossRef N. Suskin, R.S. McKelvie, R.J. Burns et al., Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 21, 1368–1375 (2000)PubMedCrossRef
50.
go back to reference W. Doehner, D. Gathercole, M. Cicoira et al., Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int. J. Cardiol. 138, 19–24 (2010)PubMedCrossRef W. Doehner, D. Gathercole, M. Cicoira et al., Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int. J. Cardiol. 138, 19–24 (2010)PubMedCrossRef
51.
go back to reference A. Holmäng, P. Björntorp, The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand. 146, 505–510 (1992)PubMedCrossRef A. Holmäng, P. Björntorp, The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand. 146, 505–510 (1992)PubMedCrossRef
52.
go back to reference D. Kapoor, E. Goodwin, K.S. Channer, T.H. Jones, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocr. 154, 899–906 (2006)CrossRef D. Kapoor, E. Goodwin, K.S. Channer, T.H. Jones, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocr. 154, 899–906 (2006)CrossRef
53.
go back to reference A. Mortara, M.T. La Rovere, G.D. Pinna et al., Arterial baroreflex modulation of heart rate in chronic heart failure. Clinical and hemodynamic correlates and prognostic implications. Circulation 96, 3450–3458 (1997)PubMedCrossRef A. Mortara, M.T. La Rovere, G.D. Pinna et al., Arterial baroreflex modulation of heart rate in chronic heart failure. Clinical and hemodynamic correlates and prognostic implications. Circulation 96, 3450–3458 (1997)PubMedCrossRef
54.
go back to reference R.B. Simerly, C. Chang, M. Muramatsu, L.W. Swanson, Distribution of androgen and estrogen mRNA-containing cells in the rat brain: an in situ hybridization study. J. Comp. Neurol. 294, 76–95 (1990)PubMedCrossRef R.B. Simerly, C. Chang, M. Muramatsu, L.W. Swanson, Distribution of androgen and estrogen mRNA-containing cells in the rat brain: an in situ hybridization study. J. Comp. Neurol. 294, 76–95 (1990)PubMedCrossRef
55.
go back to reference G.R. Ward, A.A. Abdel-Rahman, Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats. BMC Pharmacol. 6, 2 (2006)PubMedCrossRef G.R. Ward, A.A. Abdel-Rahman, Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats. BMC Pharmacol. 6, 2 (2006)PubMedCrossRef
56.
go back to reference F. Altamirano, C. Oyarce, P. Silva et al., Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J. Endocrinol. 202, 299–307 (2009)PubMedCrossRef F. Altamirano, C. Oyarce, P. Silva et al., Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J. Endocrinol. 202, 299–307 (2009)PubMedCrossRef
57.
go back to reference T. Papamitsou, D. Barlaggiannis, V. Papaliagkas, E. Kotadinou, M. Dermentzopoulou-Theodoridou, Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells: an ultrastructural and immunohistochemical study. Med. Sci. Monit. 17, 266–273 (2011) T. Papamitsou, D. Barlaggiannis, V. Papaliagkas, E. Kotadinou, M. Dermentzopoulou-Theodoridou, Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells: an ultrastructural and immunohistochemical study. Med. Sci. Monit. 17, 266–273 (2011)
Metadata
Title
Testosterone and heart failure
Authors
Maurizio Volterrani
Giuseppe Rosano
Ferdinando Iellamo
Publication date
01-10-2012
Publisher
Springer US
Published in
Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9725-9

Other articles of this Issue 2/2012

Endocrine 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.